Oppenheimer on Immunovant (IMVT): today's weakness on Ph3 topline misses a 'buying opprotunity'
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $54.00 price target on Immunovant (NASDAQ: IMVT)The analyst commented, "Topline misses ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
